Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer

Gut. 1998 May;42(5):618-22. doi: 10.1136/gut.42.5.618.

Abstract

Background: Helicobacter pylori eradication therapy is routinely used for treating patients with peptic ulcer disease.

Aims: To assess the value of symptomatic response to H pylori eradication therapy as a marker of post-treatment H pylori status.

Patients and methods: One hundred and nine dyspeptic patients with active duodenal or gastric ulceration association with H pylori infection had their symptoms measured by a validated questionnaire before and three months following H pylori eradication therapy. The symptomatic response was compared with post-treatment H pylori status as determined by the 14C urea breath test.

Results: An eradication rate of 84% was achieved. Of the 92 patients eradicated of H pylori, 47% experienced complete or near complete resolution of dyspepsia. Of the 17 patients in whom the infection was not eradicated, only one (6%) experienced resolution of dyspepsia. Resolution of dyspepsia was therefore a powerful predictor of eradication of H pylori with a predictive value of 98%. In contrast, persistence of dyspepsia was a weak predictor of persisting infection with a predictive value of only 25%. Excluding patients with endoscopic evidence of coexisting oesophagitis and/or retrosternal discomfort or reflux at initial presentation did not increase the predictive value of persisting dyspepsia for persisting infection.

Conclusions: Complete resolution of dyspeptic symptoms is a powerful predictor of eradication of H pylori infection in ulcer patients. Persistence of symptoms is a weak predictor of persisting infection and patients with persisting dyspepsia must have their H pylori status rechecked to guide future management.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Ulcer Agents / therapeutic use
  • Antitrichomonal Agents / therapeutic use
  • Breath Tests
  • Drug Therapy, Combination
  • Dyspepsia / microbiology*
  • Female
  • Helicobacter Infections / diagnosis
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Omeprazole / therapeutic use
  • Organometallic Compounds / therapeutic use
  • Penicillins / therapeutic use
  • Peptic Ulcer / complications
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / microbiology
  • Predictive Value of Tests
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Antitrichomonal Agents
  • Organometallic Compounds
  • Penicillins
  • Metronidazole
  • Amoxicillin
  • bismuth tripotassium dicitrate
  • Omeprazole